Intranasal COVID-19 vaccine tops vaccine injection

By The Science Advisory Board staff writers

July 28, 2022 -- Ohio researchers have discovered a new way of delivering the COVID-19 vaccine: up the nose. It could one day be incorporated into the existing measles-mumps-rubella (MMR) vaccine as a way to produce COVID-19 immunity in kids.

Scientists from The Ohio State University wanted to make a vaccine for infants and children that could protect them against four pathogens (measles, mumps, rubella, and SARS-CoV-2) in a single immunization program.

They used a prefusion version of the SARS-CoV-2 spike protein and the spike was locked into form by changing six of its amino acids to prolines. Experiments comparing the six-proline protein, 6P, to a spike protein with two prolines, 2P, showed the 6P induces significantly more neutralizing antibodies in mice and golden Syrian hamsters than the 2P version (Proceedings of the National Academy of Sciences, July 27, 2022).

Specifically, the researchers found the 6P antigen is about 8.5 times better than 2P, which means more antibody production. The study used a mumps vaccine strain that has been a component of the current MMR vaccine used in children since the 1960s. The mumps virus genome is more amenable than measles to insertion of the spike protein gene. Once the 6P spike protein gene is inserted into the genome, the recombinant mumps virus replicates more slowly but is genetically stable and grows well in a World Health Organization-approved cell line for vaccine production, the researchers added.

They also compared the 6P spike protein vaccine candidate's effectiveness with a 2P version in mumps and to mumps without the spike protein in mice engineered to be highly susceptible to mumps infection and in golden Syrian hamsters. In all experiments, the 6P vaccine produced higher concentrations of neutralizing antibodies after vaccination, and, after introduction of a SARS-CoV-2 virus, protection from lung damage and significantly fewer viral particles in the lungs and nasal cavity.

The research team also developed a rapid recombination system that allows for the insertion of any antigen into a mumps or measles virus in a week so that the MMR vaccine can be rapidly updated to protect against new SARS-CoV-2 variants as they emerge.

In the study, animals were vaccinated by both injections and drops into the nose. The nasal drops provided better protection against the coronavirus by inducing not only system-wide antibodies, but a broad response of IgA on mucosal surfaces of the airways as well. Antibodies in the bloodstream do not protect the mucosal site of the airways very well, which is the initial site of infection with SARS-CoV-2. The intranasal vaccine may be the next generation of COVID-19 vaccine because it can induce robust IgA to directly neutralize the SARS-CoV-2 in the nose and airways tissues, according to the researchers.


Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.